LEXARIA BIOSCIENCE ($LEXX) is expected to release its quarterly earnings data on Thursday, July 10th before market open, per Finnhub. Analysts are expecting revenue of $93,156 and earnings of -$0.16 per share.
You can see Quiver Quantitative's $LEXX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
LEXARIA BIOSCIENCE Hedge Fund Activity
We have seen 10 institutional investors add shares of LEXARIA BIOSCIENCE stock to their portfolio, and 8 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC removed 460,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $786,600
- INVENOMIC CAPITAL MANAGEMENT LP added 139,216 shares (+33.9%) to their portfolio in Q1 2025, for an estimated $238,059
- TORONTO DOMINION BANK added 130,025 shares (+inf%) to their portfolio in Q1 2025, for an estimated $222,342
- MORGAN STANLEY removed 20,229 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $34,591
- WEALTH ENHANCEMENT ADVISORY SERVICES, LLC added 17,136 shares (+124.0%) to their portfolio in Q1 2025, for an estimated $29,302
- BYRNE ASSET MANAGEMENT LLC added 15,905 shares (+122.3%) to their portfolio in Q1 2025, for an estimated $27,197
- SCOTIA CAPITAL INC. removed 10,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $17,100
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
LEXARIA BIOSCIENCE Analyst Ratings
Wall Street analysts have issued reports on $LEXX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 07/01/2025
To track analyst ratings and price targets for LEXARIA BIOSCIENCE, check out Quiver Quantitative's $LEXX forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
